https://salubrisbio.eigercreative.co.uk/2022/03/08/salubris-biotherapeutics-announces-32-million-financing-to-advance-novel-complex-biologics-for-cardiovascular-oncology-and-neurodegenerative-diseases/ 2022-03-10T09:14:59+00:00 https://salubrisbio.eigercreative.co.uk/2022/09/29/salubris-biotherapeutics-announces-updated-phase-1b-data-demonstrating-that-jk07-the-first-investigational-antibody-fusion-protein-for-heart-failure-resulted-in-clinically-meaningful-improvements-in/ 2022-09-29T08:07:44+00:00 https://salubrisbio.eigercreative.co.uk/2023/05/22/salubris-biotherapeutics-presents-positive-updates-from-phase-1b-clinical-trial-of-jk07-in-late-breaking-session-at-the-european-society-of-cardiology-heart-failure-2023-congress/ 2023-05-22T10:26:25+00:00 https://salubrisbio.eigercreative.co.uk/2023/10/10/salubris-biotherapeutics-presents-positive-6-month-data-from-phase-1b-clinical-trial-of-jk07-in-late-breaking-session-at-the-heart-failure-society-of-america-annual-meeting-2023/ 2023-10-10T09:22:11+00:00 https://salubrisbio.eigercreative.co.uk/2023/10/24/salubris-biotherapeutics-presents-positive-initial-data-from-phase-1b-2-clinical-trial-of-jk08-at-the-european-society-for-medical-oncology-annual-congress-2023/ 2023-10-24T08:14:44+00:00 https://salubrisbio.eigercreative.co.uk/2024/04/22/salubris-biotherapeutics-announces-35-million-in-financing-and-provides-pipeline-progress-update/ 2024-06-21T08:50:56+00:00 https://salubrisbio.eigercreative.co.uk/2024/08/05/salubris-biotherapeutics-announces-european-medicines-agency-approval-to-initiate-a-phase-1-clinical-trial-of-jk06-a-5t4-targeted-adc-in-solid-tumors/ 2024-08-05T05:09:18+00:00 https://salubrisbio.eigercreative.co.uk/2023/03/28/salubris-biotherapeutics-announces-35-million-financing-to-advance-development-activities-and-provides-pipeline-updates/ 2024-10-23T11:05:39+00:00 https://salubrisbio.eigercreative.co.uk/2025/01/22/salubris-biotherapeutics-announces-positive-interim-data-from-the-phase-2-trial-of-jk07-in-heart-failure/ 2025-02-18T12:01:32+00:00